ReviewCurrent atherosclerosis reports2018
Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.
Review in Current atherosclerosis reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Outcomes following percutaneous coronary intervention in patients with cancer.International journal of cardiology · 2020Pooled it
- Anticoagulation challenges in cancer patients: prevention, detection, and treatment strategies.Cardio-oncology (London, England) · 2026Review
- Effect of Adjuvant Treatments on Recipient Vessel Diameter for Free Flap Breast Reconstruction Using Computed Tomographic Angiography Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Cancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors.Oncology research · 2026Review
- A Diagnostic Dilemma Upon Discovery of a Left Ventricle Mass: A Case Report.Clinical case reports · 2025Article
- Management of Stable Coronary Artery Disease and Acute Coronary Syndrome in Patients with Cancer.Current cardiology reports · 2025Review
- Article
- Integrating deep learning in public health: a novel approach to PICC-RVT risk assessment.Frontiers in public health · 2024Article
- Article
- Mechanisms of Myocardial Ischemia in Cancer Patients: A State-of-the-Art Review of Obstructive Versus Non-Obstructive Causes.Reviews in cardiovascular medicine · 2022Review
- 5-Oxo-hexahydroquinoline and 5-oxo-tetrahydrocyclopentapyridine derivatives as promising antiproliferative agents with potential apoptosis-inducing capacity.Molecular diversity · 2022Article
- Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Cardiac Computed Tomography in Cardio-Oncology:JACC. CardioOncology · 2021Review
- Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report.European heart journal. Case reports · 2021Article
- Machine Learning-Augmented Propensity Score Analysis of Percutaneous Coronary Intervention in Over 30 Million Cancer and Non-cancer Patients.Frontiers in cardiovascular medicine · 2021Article
- Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology.Frontiers in cardiovascular medicine · 2021Review
- Evaluating the Severity of Coronary Artery Disease in Patients Treated with Chemotherapy: The Further Need for Cardio-Oncology.Arquivos brasileiros de cardiologia · 2020Article
- The Onco-cardiologist Dilemma: to Implant, to Defer, or to Avoid Transcatheter Aortic Valve Replacement in Cancer Patients with Aortic Stenosis?Current cardiology reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewNumerous chemotherapeutic agents have been associated with the development of ischemia and arterial thrombosis. As newer therapies have been developed to treat cancer, some of these chemotherapy drugs have been implicated in the development of vascular disease. In this review, we will summarize the most common chemotherapeutic drug classes that may play a role in the development of ischemic heart disease. RECENT
findingsAngiogenesis inhibitors, alkylating agents, antimetabolites, antimicrotubules, and proteasome inhibitors have a number of cardiovascular toxicities. The possible mechanisms of action of these drugs leading to ischemic complications are varied but include endothelial dysfunction, platelet aggregation, reduced levels of nitrous oxide (NO), and elevated levels of reactive oxygen species (ROS), and vasospasm. While some drugs act through multiple pathways that result in the development of ischemic heart disease, others such as the antimetabolites and antimicrotubules appear to primarily cause vasospasm. Furthermore, while aromatase inhibitors increase the risk of heart disease in comparison to tamoxifen in large studies, this finding likely occurs because of a protective role of tamoxifen on cardiovascular risk factors rather than a direct effect of aromatase inhibitors. Angiogenesis inhibitors, alkylating agents, antimetabolites, antimicrotubules, and proteasome inhibitors can lead to ischemic complications in patients with cancer. Many of these drugs have proven to be effective in improving cancer prognosis, but their possible cardiovascular effects have to be carefully monitored and treated. Treatment of ischemic complications in the setting of cancer therapy should focus on the optimal medical management of known cardiovascular risk factors and follow an evidence-based approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.